Proposed FTC Order will Prohibit Telehealth Firm Cerebral from Using or Disclosing Sensitive Data for Advertising Purposes, and Require it to Pay $7 Million
Retrieved on:
星期四, 四月 18, 2024
Key Points:
File
Proposed FTC Order will Prohibit Telehealth Firm Cerebral from Using or Disclosing Sensitive Data for Advertising Purposes, and Require it to Pay $7 Million
Retrieved on:
星期四, 四月 18, 2024
The order must be approved by the court before it can go into effect.
Key Points:
- The order must be approved by the court before it can go into effect.
- “As the Commission’s complaint lays out, Cerebral violated its customers’ privacy by revealing their most sensitive mental health conditions across the Internet and in the mail,” said FTC Chair Lina M. Khan.
- “To address this betrayal, the Commission is ordering a first-of-its-kind prohibition that bans Cerebral from using any health information for most advertising purposes."
- Cerebral provides online mental health and related services on a negative option basis, which means consumers are automatically charged unless they cancel those services.
- Despite promising that consumers could “cancel anytime,” Cerebral required its clients to navigate a complex, multi-step, and often multi-day process to cancel.
- The complaint alleges that the company continued to charge consumers while it slow-walked consumers’ cancellation requests, which cost consumers millions in additional charges.
- The proposed order, which must be approved by a federal court before it can go into effect, only applies to Cerebral.
- The Commission voted 3-0 to refer the complaint against Cerebral and Robertson and a stipulated final order with Cerebral to the Department of Justice for filing.
- The DOJ filed the complaint and stipulated order in the U.S. District Court for the Southern District of Florida.
Alcohol Addiction Treatment Firm will be Banned from Disclosing Health Data for Advertising to Settle FTC Charges that It Shared Data Without Consent
Retrieved on:
星期五, 四月 12, 2024
Key Points:
Alcohol Addiction Treatment Firm will be Banned from Disclosing Health Data for Advertising to Settle FTC Charges that It Shared Data Without Consent
Retrieved on:
星期五, 四月 12, 2024
The Federal Trade Commission has taken action against an alcohol addiction treatment service for allegedly disclosing users’ personal health data to third-party advertising platforms, including Meta and Google, for advertising without consumer consent, after promising to keep such information confidential.
Key Points:
- The Federal Trade Commission has taken action against an alcohol addiction treatment service for allegedly disclosing users’ personal health data to third-party advertising platforms, including Meta and Google, for advertising without consumer consent, after promising to keep such information confidential.
- As part of a proposed order settling the FTC allegations, New York-based Monument, Inc. will be banned from disclosing health information for advertising and must obtain users’ affirmative consent before sharing health information with third parties for any other purpose.
- “This action continues the FTC’s work to ensure strict limits on how firms handle sensitive health data, rather than putting the onus on consumers to protect themselves,” said Samuel Levine, Director of the FTC’s Bureau of Consumer Protection.
- Monument used these pixels and APIs to track “standard” and “custom events,” meaning instances in which consumers interacted with Monument’s website.
- If the company is found to have misrepresented its finances, it will be required to pay the full amount.
- The Commission voted 3-0 to refer the complaint and stipulated final order to the Department of Justice for filing.
- The DOJ filed the complaint and stipulated order in the U.S. District Court for the District of Columbia.
EQS-News: PlusPlus Capital Announces that PlusPlus Capital Financial S.à r.l. Filed Reorganization Petition
Retrieved on:
星期三, 四月 10, 2024
PlusPlus Capital Announces that PlusPlus Capital Financial S.à r.l.
Key Points:
- PlusPlus Capital Announces that PlusPlus Capital Financial S.à r.l.
- PlusPlus Capital Announces that PlusPlus Capital Financial S.à r.l.
- PlusPlus Capital (“PPC”), a leading pan-Baltic and Finnish technology-driven receivables management group, announces that PlusPlus Capital Financial S.à r.l.
- PlusPlus Capital will inform about the ruling of the Luxembourg court on the reorganization process of PlusPlus Capital Financial S.à r.l.
EQS-News: PlusPlus Capital Announces Reorganization Petition to be filed by PlusPlus Capital Financial S.à r.l. – Invitation to update call on 25 March 2024
Retrieved on:
星期三, 四月 10, 2024
PlusPlus Capital Announces Reorganization Petition to be filed by PlusPlus Capital Financial S.à r.l.
Key Points:
- PlusPlus Capital Announces Reorganization Petition to be filed by PlusPlus Capital Financial S.à r.l.
- PlusPlus Capital Announces Reorganization Petition to be filed by PlusPlus Capital Financial S.à r.l.
- PlusPlus Capital (“PPC”), a leading pan-Baltic and Finnish technology-driven receivables management group, announces that the Management Board of PlusPlus Capital Financial S.à r.l., representing the subsidiary and largest creditor of the parent company AS PlusPlus Capital, intends to vote in favor of the reorganization plan of AS PlusPlus Capital , as the ability of PlusPlus Financial S.à r.l.
- PlusPlus Capital cordially invites investors and analysts to an update call with the Management on 25 March 2024, 10.00 CET.
bluebird bio, Inc. (BLUE) Class Action Notice: Robbins LLP Reminds Stockholders of Lead Plaintiff Deadline in Class Action Against bluebird bio, Inc.
Retrieved on:
星期二, 四月 9, 2024
Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
Key Points:
- Bluebird is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases.
- For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
- A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.
- If you choose to take no action, you can remain an absent class member.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, and Anavex and Encourages Investors to Contact the Firm
Retrieved on:
星期二, 四月 9, 2024
The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Key Points:
- The Company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
- In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
- On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.
- For more information on the Anavex class action go to: https://bespc.com/cases/AVXL
Rio2 Announces Receipt of RCA Resolution for the Fenix Gold Project & C$10 Million Private Placement
Retrieved on:
星期一, 四月 8, 2024
VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Rio2 Limited (“Rio2” or the “Company”) (TSXV: RIO; OTCQX: RIOFF; BVL: RIO) today announces that its Chilean subsidiary, Fenix Gold Limitada (“Fenix Gold”), has received the formal Resolución de Calificación Ambiental (Environmental Qualification Resolution, or RCA) for its Fenix Gold Project (the “Project”) located in the Maricunga Mineral Belt of the Atacama Region, Chile.
Key Points:
- The RCA has been issued following the approval of the Project’s Environmental Impact Assessment previously announced on December 20, 2023.
- The receipt of the RCA now allows Fenix Gold to advance permitting activities for the Project.
- The current timing for receipt of these principal permits is by the end of July 2024.
- The Company is seeking to finance a substantial component of the initial capital costs by way of Project related debt.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – VTYX
Retrieved on:
星期一, 四月 8, 2024
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.
Key Points:
- NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) and certain officers.
- To discuss this action, contact Danielle Peyton at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
- Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.